A recent study reveals that people who come off blockbuster GLP-1 drugs like Mounjaro or Wegovy can put back on reduced body mass much more quickly than those who end traditional diet and exercise regimens.
Research printed in a leading health publication shows that while overweight people often shed substantial amounts of their body weight while undergoing treatment, the weight returns at an average rate of nearly a kilo each month once they quit.
"People using these treatments must be aware of the danger of quick weight regain when the therapy ends," stated researcher Dr. Susan Jebb.
This pace of recovery means a return to starting mass within about one and a half years.
Comparing Approaches
The study, which examined 37 of studies involving over 9,000 of participants, contrasted the results of GLP-1 agonists with other pills.
Researchers emphasize that people who shed pounds through diet and exercise generally have a more gradual weight regain—perhaps 0.1 kg a month—once they finish.
Explaining the Rapid Regain
Nutrition scientists propose the way of the drugs explains the amplified rebound.
GLP-1 drugs imitate a body's own chemical called glucagon-like peptide-1, which helps regulate appetite.
"Sustained high doses of the hormone levels far above than normal could lead to the system to produce less of its own natural GLP-1, and could reduce sensitivity to its actions," explained Dr. Adam Collins, a dietetics specialist.
"Withdrawal of this GLP-1 'fix' means appetite is unsuppressed, making binge eating a significant risk."
An Ongoing Issue?
The NHS recommend the jabs for people with weight-linked health risks, alongside recommended diet and exercise modifications.
Professionals contend that, due to the likelihood of weight regain, the therapy might need to be life-long.
This view is echoed by pharmaceutical companies, who note that the findings "underscore the long-term character of excess weight," similar to managing conditions like high blood pressure.
User Experiences
People who have come off the jabs describe a sudden resurgence of cravings.
"It was like something flipping and you're instantly ravenous," recalled a patient.
This challenge is compounded if individuals have not adopted lasting dietary or behavioural changes during treatment.
Widespread Use
Recent estimates show that a significant number of people in the UK have used these injections in the last 12 months, with interest being substantial.
- Use is higher among women compared to men.
- The middle-aged age group shows the greatest level of interest.
- Many access the drugs through private healthcare rather than public health services.
In conclusion, clinicians stress that while these medications are potent agents for weight loss, they are not a standalone cure and lasting health benefits relies on integrated behavioural support.
